Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells

• Published in: Frontiers in immunology Vol. 9; p. 824
• Main Authors: Zhu, Liya, Oh, Ji Min, Gangadaran, Prakash, Kalimuthu, Senthilkumar, Baek, Se Hwan, Jeong, Shin Young, Lee, Sang-Woo, Lee, Jaetae, Ahn, Byeong-Cheol
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.04.2018
• Subjects: Animals; Apoptosis; Brain Neoplasms - immunology; Brain Neoplasms - therapy; Cell Line, Tumor; Cytokines - immunology; Disease Models, Animal; exosomes; Exosomes - immunology; Female; Flow Cytometry; glioblastoma; Glioblastoma - immunology; Glioblastoma - therapy; Heterografts; Immunology; Immunotherapy; Killer Cells, Natural - immunology; Mice; Mice, Inbred BALB C; Mice, Nude; natural killer cells; tumor targeting; natural killer cells; tumor targeting; glioblastoma; exosomes; immunotherapy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2018.00824

Glioblastoma is a highly aggressive primary brain tumor that is resistant to radiotherapy and chemotherapy. Natural killer (NK) cells have been used to treat incurable cancers. Recent studies have investigated the effectiveness of NK-cell-derived exosomes (NK-Exo) for treating incurable cancers such as melanoma, leukemia, and neuroblastoma; however, NK-Exo have not been used to treat glioblastoma. In the present study, we investigated the antitumor effects of NK-Exo against aggressive glioblastoma both and and determined the tumor-targeting ability of NK-Exo by performing fluorescence imaging. U87/MG cells were transfected with the enhanced firefly luciferase (effluc) and thy1.1 genes; thy1.1-positive cells were selected using microbeads. U87/MG/F cells were assessed by reverse transcription polymerase chain reaction (RT-PCR), western blotting, and luciferase-activity assays. NK-Exo were isolated by ultracentrifugation, purified by density gradient centrifugation, and characterized by transmission electron microscopy, dynamic light scattering (DLS), nanoparticle-tracking analysis (NTA), and western blotting. Cytokine levels in NK-Exo were compared to those in NK cells and NK-cell medium by performing an enzyme-linked immunosorbent assay (ELISA). NK-Exo-induced apoptosis of cancer cells was confirmed by flow cytometry and western blotting. therapeutic effects and specificity of NK-Exo against glioblastoma were assessed in a xenograft mouse model by fluorescence imaging. Xenograft mice were treated with NK-Exo, which was administered seven times through the tail vein. Tumor growth was monitored by bioluminescence imaging (BLI), and tumor volume was measured by ultrasound imaging. The mice were intraperitoneally injected with dextran sulfate 2 h before NK-Exo injection to decrease the liver uptake and increase the tumor specificity of NK-Exo. RT-PCR and western blotting confirmed the gene and protein expression of effluc in U87/MG/F cells, with the bioluminescence activity of U87/MG/F cells increasing with an increase in cell number. NTA and DLS results indicated that the size of NK-Exo was ~100 nm, and the western blot results confirmed that NK-Exo expressed exosome markers CD63 and Alix. We confirmed the cytotoxic effects of NK-Exo on U87/MG/F cells by performing BLI, and the killing effect on U87/MG and U87MG/F cells was measured by CCK-8 and MTT assays (  < 0.001). ELISA results indicated that NK-Exo contained tumor necrosis factor-α and granzyme B. NK-Exo treatment inhibited tumor growth compared to in control mice (  < 0.001), and pretreatment of xenograft mice with dextran sulfate 2 h before NK-Exo treatment increased the antitumor effect of NK-Exo (  < 0.01) compared to in control and NK-Exo-alone-treated mice. NK-Exo targeted and exerted antitumor effects on glioblastoma cells both and , suggesting their utility in treating incurable glioblastoma.